Brief: PepGen Reports Positive Data From Phase 1 Trial Of PGN-EDO51 For Treatment Of Duchenne Muscular Dystrophy

PepGen

28/09/2022 11:06

Sept 28 (Reuters) - PepGen Inc  PEPG.O :
    * PEPGEN REPORTS POSITIVE DATA FROM PHASE 1 TRIAL OF
PGN-EDO51 FOR
THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
    * PEPGEN INC - PGN-EDO51 WAS GENERALLY WELL-TOLERATED
    * PEPGEN INC - PEPGEN PLANS TO INITIATE A PHASE 2A MULTIPLE
ASCENDING DOSE (MAD) CLINICAL TRIAL IN DUCHENNE MUSCULAR
DYSTROPHY (DMD) PATIENTS IN 1H 2023
    * PEPGEN INC - DATA SUPPORTS POTENTIAL OF PEPGEN'S ENHANCED
DELIVERY OLIGONUCLEOTIDE (EDO) PLATFORM IN NEUROMUSCULAR
DISEASES

Source text for Eikon:  ID:nGNX3cgqBS 
Further company coverage:  PEPG.O 
 ((Reuters.Briefs@thomsonreuters.com;;))